Melatonin Improves Erythropoietin Hyporesponsiveness via Suppression of Inflammation

Author(s): Evan Noori Hameed, Haydar F. Hadi AL Tukmagi, Hayder Ch Assad Allami*.

Journal Name: Reviews on Recent Clinical Trials

Volume 14 , Issue 3 , 2019

Become EABM
Become Reviewer

Abstract:

Background: Inadequate response to Erythropoietin Stimulating Agents (ESA) despite using relatively larger doses regimen represents a potential risk factor of Cardiovascular (CV) related mortality in addition to health-care economic problems in anemic patients with Chronic Kidney Disease (CKD). Erythropoietin (EPO) hyporesponsiveness related to inflammation has been increased progressively. Melatonin is well known as a potent anti-inflammatory agent. Therefore, the current study was designed to evaluate whether melatonin could improve anemic patients response to EPO.

Methods: This single controlled clinical study was carried out in 41 CKD patients with hemoglobin (Hb) levels less than 11g/dl divided randomly in a 1:1 ratio into 2 groups; treatment group who received 5mg melatonin plus their regular treatments and control group who received their regular treatments only. Hematological and iron status parameters include Hb level, serum iron (S. iron), Transferrin Saturation Ratio (TSAT) and serum ferritin (S. ferritin) in addition to inflammatory parameters that include tissue necrotic factor alfa (TNF-α), interleukin-1beta (IL-1β) and interleukin-6 (IL-6) determined before and after 12 weeks of treatment.

Results: Melatonin remarkably increases the Hb level with a significant increase in S. iron and TSAT compared to baseline. The elevation of S. iron and TSAT was significantly higher in the melatonin group. Additionally, all inflammatory markers estimated were reduced significantly by melatonin compared to base line and control group.

Conclusion: The results of the current study showed that melatonin has an advantageous effect on improving EPO response in anemic patients with CKD.

Keywords: Anemia, erythropoietin, hyporesponsiveness, inflammation, kidney disease, melatonin.

[1]
Johansen KL, Finkelstein FO, Revicki DA, et al. Systematic review and meta-analysis of exercise tolerance and physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. Am J Kidney Dis 2010; 55(3): 535-48.
[2]
Hung SC, Lin YP, Tarng DC. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years? J Formos Med Assoc 2014; 113(1): 3-10.
[3]
Ogawa T, Shimizu H, Kyono A, et al. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: A single-center cohort study. Int Urol Nephrol 2014; 46(1): 151-9.
[4]
Ogawa T, Nitta K. Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients. Contrib Nephrol 2015; 185: 76-86.
[5]
Samavat S, Nafar M, Khoshdel A, Alipour-Abedi B. Factors contributing to erythropoietin hyporesponsiveness among hemodialysis patients: A cross-sectional multicenter study. Nephrourol Mon 2017.
[6]
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (KDIGO 2012) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2017; 2017: 1-150.
[7]
Nand N, Chauhan V, Seth S, Batra N, Savio Dsouza S. Inflammation and erythropoietin hyporesponsiveness: Role of pentoxifylline, an anti TNF-α; agent. J Ind Acad Clin Med 2016; 17(1): 16-20.
[8]
Cormack-Aboud FC. Inflammation in chronic kidney disease: Potential causes and possible therapies. medscape nephrology. Available from: https://www.medscape.org/viewarticle/549377.
[9]
Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents--what do we know and what needs to be clarified? Nephrol Dial Transplant 2005; 20(8)(Suppl. 8): i2-7.
[10]
Rubab Z, Amin H, Abbas K, Hussain S, Ullah MI, Mohsin S. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis. Saudi J Kidney Dis Transpl 2015; 26(1): 19-25.
[11]
Khalil SK, Amer HA, El Behairy AM, Warda M. Oxidative stress during erythropoietin hyporesponsiveness anemia at end stage renal disease: Molecular and biochemical studies. J Adv Res 2016; 7(3): 348-58.
[12]
Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014; 28(4): 671-81. [vi.].
[13]
Krishnan AR, Trinde D, Chua AC, Chakera A, Ramm GA, Olynyk JK. Anaemia of chronic kidney disease: What we know now. J Ren Hepat Disord 2017; 1(1): 11-9.
[14]
Hasegawa T, Zhao J, Fuller DS, et al. Erythropoietin hyporesponsiveness in dialysis patients: Possible role of statins. Am J Nephrol 2017; 46(1): 11-7.
[15]
Meng X, Li Y, Li S, et al. Dietary sources and bioactivities of melatonin. Nutrients 2017; 9(4): 367.
[16]
Sun H, Wang X, Chen J, et al. Melatonin treatment improves insulin resistance and pigmentation in obese patients with acanthosis nigricans. Int J Endocrinol 2018; 2018: 2304746.
[17]
El-Sharkawy H, Elmeadawy S, Elshinnawi U, Anees M. Is dietary melatonin supplementation a viable adjunctive therapy for chronic periodontitis? A randomized controlled clinical trial 2019. J Periodontal Res 2019; 54: 190-7.
[18]
Koch BC, van der Putten K, Van Someren EJ, et al. Impairment of endogenous melatonin rhythm is related to the degree of chronic kidney disease (CREAM study). Nephrol Dial Transplant 2010; 25(2): 513-9.
[19]
Obayashi K, Saeki K, Kurumatani N. Higher melatonin secretion is associated with lower leukocyte and platelet counts in the general elderly population: The HEIJO-KYO cohort. J Pineal Res 2015; 58(2): 227-33.
[20]
Eleftheriadis T, Liakopoulos V, Antoniadi G, Stefanidis I. Which is the best way for estimating transferrin saturation? Ren Fail 2010; 32(8): 1022-3.
[21]
Khamis SA, Yassin YS, Dawood AA, El Zorkany KA, Mahros EG. The correlation between residual renal function and inflammation in chronic hemodialysis patients. Menoufia Med J 2017; 30(3): 679-86.
[22]
Rogers J, Lacroix L, Durmowitz G, Kasschau K, Andriotakis J, Bridges KR. The role of cytokines in the regulation of ferritin expression. Adv Exp Med Biol 1994; 356: 127-32.
[23]
de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness NDT Plus 2009; 2(1)(Suppl_1). : i18-26.
[24]
Labonia W, Rubio D, Arias C. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients. Nephrology (Carlton) 2005; 10(6): 583-7.
[25]
Burchakov DI, Uspenskaya YB. Antioxidant, anti-inflammatory and sedative effects of melatonin: results of clinical trials Zh Nevrol Psikhiatr Im S S Korsakova 2017; 117(4. Vyp. 2). : 67-73.
[26]
Mauriz JL, Collado PS, Veneroso C, Reiter RJ, González-Gallego J. A review of the molecular aspects of melatonin’s anti-inflammatory actions: Recent insights and new perspectives. J Pineal Res 2013; 54(1): 1-14.
[27]
Teke HU, Cansu DU, Yildiz P, Temiz G, Bal C. Clinical significance of serum IL-6, TNF-α; Hepcidin, and EPO levels in anemia of chronic disease and iron deficiency anaemia: The laboratory indicators for anemia. Biomed Res 2017; 28(6): 2704-10.
[28]
Ali TM, Genina AM, Abo-Salem OM. The determinants of hepcidin level in chronic kidney disease and hemodialysis Saudi patients. Beni-Suef Univ J Basic Appl Sci 2014; 3(2): 133-9.
[29]
Wang CY, Babitt JL. Hepcidin regulation in the anemia of inflammation. Curr Opin Hematol 2016; 23(3): 189-97.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2019
Page: [203 - 208]
Pages: 6
DOI: 10.2174/1574887114666190528120357
Price: $65

Article Metrics

PDF: 35
HTML: 1